Division of Pediatric Blood and Marrow Transplantation, University of California, San Francisco, 505 Parnassus Avenue, M-659, San Francisco, CA 94143-1278, USA.
Immunol Allergy Clin North Am. 2010 Feb;30(1):125-42. doi: 10.1016/j.iac.2009.10.004.
Inherited defects in components of the nonhomologous end-joining DNA repair mechanism produce a T-B-NK+ severe combined immunodeficiency disease (SCID) characterized by heightened sensitivity to ionizing radiation. Patients with the radiosensitive form of SCID may also have increased short- and long-term sensitivity to the alkylator-based chemotherapy regimens that are traditionally used for conditioning before allogeneic hematopoietic cell transplantation (HCT). Known causes of radiosensitive SCID include deficiencies of Artemis, DNA ligase IV, DNA-dependent protein kinase catalytic subunit, and Cernunnos-XLF, all of which have been treated with HCT. Because of these patients' sensitivity to certain forms of chemotherapy, the approach to donor selection and the type of conditioning regimen used for a patient with radiosensitive SCID requires careful consideration. Significantly more research needs to be done to determine the long-term outcomes of patients with radiosensitive SCID after HCT and to discover novel nontoxic approaches to HCT that might benefit those patients with intrinsic radiosensitivity and chemosensitivity as well as potentially all patients undergoing an HCT.
非同源末端连接 DNA 修复机制的成分遗传缺陷会导致 T-B-NK+严重联合免疫缺陷病(SCID),其特征是对电离辐射高度敏感。辐射敏感型 SCID 患者在接受传统异基因造血细胞移植(HCT)前预处理的烷化剂化疗方案时,也可能会出现短期和长期的敏感性增加。已知的辐射敏感型 SCID 病因包括 Artemis、DNA 连接酶 IV、DNA 依赖性蛋白激酶催化亚基和 Cernunnos-XLF 的缺乏,这些疾病都可以通过 HCT 进行治疗。由于这些患者对某些类型的化疗药物敏感,因此需要仔细考虑辐射敏感型 SCID 患者的供者选择方法和使用的预处理方案类型。为了确定 HCT 后辐射敏感型 SCID 患者的长期结果,并发现新的非毒性 HCT 方法,以可能使那些具有内在辐射和化疗敏感性的患者以及所有接受 HCT 的患者受益,还需要进行更多的研究。